How should claims of skin laxity after filler dissolution be assessed?

A looser or emptier appearance after dissolving hyaluronic-acid filler may reflect baseline volume loss, tissue expansion, reduced oedema, incomplete dissolution or photography differences. A photograph alone cannot establish the conclusion that hyaluronidase 'dissolved the skin'.

This translation has no recorded clinical or medical-language review.

Direct answer

First verify that the material is hyaluronic acid and identify where it is located.
Baseline, pre-filler and post-dissolution standardized photographs answer different questions.
The risk-benefit calculation in urgent vascular occlusion differs from elective appearance correction.

Possible components of the visual change

Pre-existing volume loss, product added over years, migration, chronic oedema, weight change and natural ageing can all influence appearance. Removing volume may reveal the earlier contour more clearly than expected. Hyaluronidase can temporarily interact with native tissue hyaluronic acid, but one photograph cannot demonstrate permanent structural skin damage or identify the contribution of each component.

Verification and timing

Collect product label, lot, amount, plane and dates. Permanent or unknown material may not respond to hyaluronidase. Ultrasound can help locate a product pocket or oedema in selected cases. Early swelling after dissolution—or a rapid reduction of existing oedema—is not necessarily the final appearance. Assessment time depends on the reason for treatment, product and clinical findings.

Build a staged decision

For elective correction, discuss a defined target and the most limited reasonable approach; test dosing and repeat treatment vary with product and context. Injection has its own risks, including allergic reaction. In suspected vascular occlusion, time-sensitive tissue risk takes priority. Document uncertainty, alternatives and no treatment. Do not promise exact restoration of a former appearance.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Dermal Fillers (Soft Tissue Fillers)
U.S. Food and Drug Administration (FDA) · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Guideline for the Management of Hyaluronic Acid Filler-Induced Vascular Occlusion
Gillian Murray, Cormac Convery, Lee Walker, Emma Davies; Complications in Medical Aesthetics Collaborative (CMAC) · 2021
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review
Audra Janovskiene, Deividas Chomicius, Dominykas Afanasjevas, Zygimantas Petronis, Dainius Razukevicius, Egle Jagelaviciene · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation
CARE board consensus authors · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Use of Ultrasound in the Management of Hyaluronic Acid Filler Complications: An International Delphi Consensus
International expert Delphi panel · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review